Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
BHVN
STRONG SELLBiohaven Ltd. · Healthcare · United States · $2.2B · Avg Vol: $47M/d
COMPANY DESCRIPTION
Biohaven Ltd. is a biopharmaceutical company dedicated to developing and commercializing innovative therapies for rare diseases, with a particular focus on central nervous system (CNS) disorders. Formed from the spin-off of certain assets after Pfizer's acquisition of its predecessor, the company retains a pipeline of early to mid-stage candidates. BHVN aims to address significant unmet medical needs in niche neuropsychiatric and neurodegenerative conditions by leveraging established scientific expertise.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | — | — | 21.4M | — |
| EPS | -5.77 | -5.73 | -9.28 | -6.86 | — | -5.36 | — | — |
| Shares | 150.6M | 81.1M | 101.2M | 132.8M | -11.8% | 150.6M | — | — |
| Debt | 33.6M | 30.9M | 36.6M | 284.6M | 103.8% | 286.2M | — | — |
| Equity | 538.8M | 428.0M | 423.4M | 52.1M | -54.1% | — | — | — |
| Op CF | -297.7M | -331.7M | -582.5M | -609.4M | — | -594.2M | — | — |
| Inv CF | -304.8M | 129.8M | -245.0M | 300.6M | — | — | — | — |
| Fin CF | 767.6M | 211.9M | 677.8M | 439.1M | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of BHVN are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| BHVN | Biohaven Ltd.(you) | $2.2B | 20 | STRONG SELL |
| NKTR | Nektar Therapeutics | $2.4B | 22 | SELL |
| ZBIO | Zenas BioPharma, Inc. | $1.9B | 18 | STRONG SELL |
| TYRA | Tyra Biosciences, Inc. | $1.8B | 21 | SELL |
| PGEN | Precigen, Inc. | $1.9B | 17 | STRONG SELL |
| ZYME | Zymeworks Inc. | $1.7B | 19 | STRONG SELL |
| MLYS | Mineralys Therapeutics, Inc. | $2.4B | 16 | STRONG SELL |
| IMNM | Immunome, Inc. | $2.5B | 17 | STRONG SELL |
| BEAM | Beam Therapeutics Inc. | $2.6B | 17 | STRONG SELL |
| SNDX | Syndax Pharmaceuticals, Inc. | $1.8B | 16 | STRONG SELL |
Peer medians: ROE -25.5% · P/E 27.6x · Gross margin 50.6%